A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity

DOI10.1016/J.JSPI.2011.10.016zbMath1232.62154OpenAlexW2047193122WikidataQ40109131 ScholiaQ40109131MaRDI QIDQ665054

Johannes E. Wolff, Peter F. Thall, Hoang Q. Nguyen, Xue-Mei Wang

Publication date: 5 March 2012

Published in: Journal of Statistical Planning and Inference (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc3249838

zbMATH Keywords

Bayesian designtreatment selection

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Medical applications (general) (92C50)

Cites Work

• Unnamed Item
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• A review of phase 2-3 clinical trial designs
• Estimating the dimension of a model
• Discrete Sequential Boundaries for Clinical Trials
• Simple Sequential Boundaries for Treatment Selection in Multi‐Armed Randomized Clinical Trials with a Control
• Approximately Optimal One-Parameter Boundaries for Group Sequential Trials
• Two-stage selection and testing designs for comparative clinical trials
• Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
• Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts
• Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Opportunities and Limitations
• A Simplex Method for Function Minimization
• Phase 2 and 3 Combination Designs to Accelerate Drug Development

This page was built for publication: A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity